AFM
DMRA

Anson Funds Management’s Damora Therapeutics DMRA Stock Holding History

Anson Funds Management’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7,341
Closed -$556K – 381
2021
Q4 		$556K Buy
+7,341
New +$577K 0.05% 220

Other funds holding DMRA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Anson Funds Management's DMRA Position: Q1 2022 in Review

Anson Funds Management sold out of Damora Therapeutics (DMRA) in Q1 2022, closing a stake of 7,341 shares — an estimated $556K sold.

Anson Funds Management first reported a position in DMRA in Q4 2021 and held it in 1 quarter. The position peaked at $556K in Q4 2021. 25 funds tracked by Wall St. Rank hold DMRA as of Q1 2022.

  • Anson Funds Management reported no remaining Damora Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Anson Funds Management sold 7,341 Damora Therapeutics shares in Q1 2022, an estimated $556K.
  • Anson Funds Management first reported a position in Damora Therapeutics in Q4 2021 and held it in 1 quarter.
  • Anson Funds Management's Damora Therapeutics position peaked at $556K in Q4 2021.
  • 25 funds tracked by Wall St. Rank held Damora Therapeutics as of Q1 2022.

Based on Anson Funds Management's 13F filing for Q1 2022, filed 12 May 2022.